• Mobocertinib gets accelerated approval for adult patients diagnosed with metastatic or locally advanced Non-Small Cell Lung Cancer with EGFR (epidermal growth factor receptor) Exon 20 Insertion.
• Approval was based on the results of the Phase 1/2 trial that demonstrated approximately 1.5 years of median duration of response.

On September 15, 2021, the FDA (Food and Drug Administration) granted accelerated approval to Mobocertinib (sold under the brand name EXKIVITY by Takeda Pharmaceuticals, Inc.) for the treatment of patients suffering from metastatic or loca...